Drug-eluting Stents More Effective, Equally As Safe As Bare Metal Stents, Clinical Trial Suggests

Late-breaking data from the HORIZONS AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction) trial reveal that after one year, use of a drug-eluting (paclitaxel) stent demonstrated significantly reduced rates of target lesion revascularization and binary angiographic restenosis when compared to the use of a bare metal stent in heart attack patients.

Read the whole article on Science Daily

More from Science Daily